The evolution of our process development of an atroposelective synthesis of KRAS G12C Inhibitor GDC-6036 is described. The selected process incorporates a key intermediate synthesis by a practical atroposelective cross-coupling which allows the manufacture of the Active Pharmaceutical Ingredient (API) GDC-6036 at &gt;100 kg scale to support our fast-moving clinical development.

Development of an atroposelective process of KRAS G12C inhibitor GDC-6036

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.